For further details see:
Shionogi gets FDA nod to begin phase 3 study of oral COVID drug S-217622home / stock / sgiof / sgiof news
For further details see:
Shionogi gets FDA nod to begin phase 3 study of oral COVID drug S-217622Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.